타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells) National Cancer Institute (NCI)·BCMA 131 trials |
|---|---|
Overview Program | Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Myeloma-Multiple; Myeloma, Plasma-Cell |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral constructs, and durable clearance of myeloma cells after multiple rechallenges |
MoA Mechanism | targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor |
MoA Biomarker | BCMA) is a high |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells) National Cancer Institute (NCI)·BCMA 131 trials |
|---|---|
Overview Program | Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Myeloma-Multiple; Myeloma, Plasma-Cell |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral constructs, and durable clearance of myeloma cells after multiple rechallenges |
MoA Mechanism | targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor |
MoA Biomarker | BCMA) is a high |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교